Beta Bionics (BBNX) Cash & Equivalents (2023 - 2026)

Beta Bionics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $30.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 28.85% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $30.2 million (down 28.85% YoY), while the FY2025 annual figure was $31.6 million, up 3.76% from the prior year.
• Cash & Equivalents came in at $30.2 million for Q1 2026 at Beta Bionics, down from $31.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $42.5 million in Q1 2025 to a low of $13.0 million in Q2 2024.
• A 4-year average of $28.7 million and a median of $30.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 169.21% in 2025 and retreated 28.85% in 2026, its largest moves.
• Beta Bionics' Cash & Equivalents stood at $26.6 million in 2023, then climbed by 14.55% to $30.4 million in 2024, then advanced by 3.76% to $31.6 million in 2025, then declined by 4.34% to $30.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $30.2 million, $31.6 million, and $38.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison